{"id":7246,"date":"2026-02-15T07:47:26","date_gmt":"2026-02-15T07:47:26","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/7246\/"},"modified":"2026-02-15T07:47:26","modified_gmt":"2026-02-15T07:47:26","slug":"kei-letter-to-roche-requesting-voluntary-license-to-patents-on-risdiplam-a-treatment-for-spinal-muscular-atrophy-sma","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/7246\/","title":{"rendered":"KEI letter to Roche requesting voluntary license to patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA)"},"content":{"rendered":"<p>This is a letter to Roche requesting a voluntary license to the patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA).  <\/p>\n<p><a href=\"https:\/\/www.keionline.org\/wp-content\/uploads\/KEI-Risdiplan-patent-license-request-8july2022.pdf\" rel=\"nofollow noopener\" target=\"_blank\">KEI-Risdiplan-patent-license-request-8july2022<\/a><\/p>\n<p>This was the August 5, 2022 response from Roche.<br \/><a href=\"https:\/\/www.keionline.org\/wp-content\/uploads\/Roche-Response-to-Risdiplam-license-request-5Aug2022.pdf\" rel=\"nofollow noopener\" target=\"_blank\">Roche-Response-to-Risdiplam-license-request\u20135Aug2022<\/a><\/p>\n<p>KEI wrote to Roche again on February 23, 2024, regarding efforts to manufacture generic risdiplam in South Africa.<br \/><a href=\"https:\/\/www.keionline.org\/wp-content\/uploads\/KEI2Thomas-Winkler-23Feb2024-risdiplam-SouthAfrica.pdf\" rel=\"nofollow noopener\" target=\"_blank\">KEI2Thomas-Winkler-23Feb2024-risdiplam-SouthAfrica<\/a><\/p>\n<p>KEI wrote to Roche on February 26, 2024, asking for a voluntary license to manufacture generic risdiplam in South Africa.<br \/><a href=\"https:\/\/www.keionline.org\/wp-content\/uploads\/KEI2Thomas-Winkler-26Feb2024-Roche-SouthAfrica-risdiplam.pdf\" rel=\"nofollow noopener\" target=\"_blank\">KEI2Thomas-Winkler-26Feb2024-Roche- SouthAfrica-risdiplam<\/a><\/p>\n<p>Roche wrote to KEI on March 19, 2024, rejecting the South Africa license request.<br \/><a href=\"https:\/\/www.keionline.org\/wp-content\/uploads\/Thomas-Winkler2KEI-19March2024-risdiplam-SouthAfrica.pdf\" rel=\"nofollow noopener\" target=\"_blank\">Thomas-Winkler2KEI-19March2024-risdiplam-SouthAfrica<\/a><\/p>\n<p>KEI wrote to Roche on May 2, 2024, asking for a meeting at Roche Headquarters to discuss a voluntary license.<br \/><a href=\"https:\/\/www.keionline.org\/wp-content\/uploads\/KEI2Thomas-Winkler-2May2024.pdf\" rel=\"nofollow noopener\" target=\"_blank\">KEI2Thomas-Winkler-2May2024<\/a><\/p>\n<p>Roche wrote to KEI on May 17, 2024, declining the meeting request.<br \/><a href=\"https:\/\/www.keionline.org\/wp-content\/uploads\/Thomas-Winkler2KEI-17May2024-risdiplam.pdf\" rel=\"nofollow noopener\" target=\"_blank\">Thomas-Winkler2KEI-17May2024-risdiplam<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"This is a letter to Roche requesting a voluntary license to the patents on risdiplam, a treatment for&hellip;\n","protected":false},"author":2,"featured_media":7247,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[5700,134,5701,5702],"class_list":["post-7246","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-risdiplam","tag-roche","tag-sma","tag-sma-foundation"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/7246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=7246"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/7246\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/7247"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=7246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=7246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=7246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}